Welcome to our dedicated page for Harte Hanks SEC filings (Ticker: HHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Harte Hanks, Inc. filings document formal disclosures for a public customer experience and data-driven marketing company. Recent 8-K reports furnish quarterly and annual results, including revenue trends, operating performance, EBITDA measures, and segment commentary tied to Customer Care, Revenue Solutions, and Fulfillment & Logistics Services.
The company’s regulatory record also includes material-event disclosures for its asset-based revolving credit facility, including amendment terms, borrowing-base mechanics, subsidiary guarantors, letter-of-credit capacity, and related financing flexibility. Definitive proxy materials cover governance, director and shareholder voting matters, executive compensation, equity awards, and pay-versus-performance disclosures.
Harte Hanks (HHS) filed its Q3 2025 10‑Q, showing softer demand across all segments and a swing to loss. Revenue was $39.5M (down 17% year over year) with operating income of $0.5M versus $1.9M a year ago. After other expenses of $0.2M and income tax expense of $2.6M, the company reported a net loss of $2.3M (basic and diluted EPS $(0.31)).
By segment in Q3: Marketing Services $8.8M and Customer Care $11.6M declined on customer turnover and program timing, while Fulfillment & Logistics $19.1M delivered stronger profitability, lifting segment operating income to $1.7M from $1.1M last year. Year to date, revenue was $119.7M (down 13.3%) and operating income was $0.5M.
Cash and equivalents were $6.5M at September 30, 2025; net cash used in operating activities was $2.5M year to date. The company extended its $25.0M revolving credit facility to June 30, 2028 at SOFR + 2.25%, had $1.0M in letters of credit outstanding, and no borrowings, leaving $24.0M available capacity. Project Elevate restructuring costs were $0.5M in Q3 and $1.5M year to date; total targeted reorganization savings across 2024–2026 are $16.0M. Shares outstanding were 7,414,794 as of October 31, 2025.
Harte Hanks (HHS) furnished a press release announcing financial results for the third quarter ended September 30, 2025. The company provided the update under Item 2.02, and the release is included as Exhibit 99.1.
The information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. Harte Hanks’ common stock trades on NASDAQ under the symbol HHS.
Harte Hanks reported lower revenue and a small net loss for the quarter ended June 30, 2025.
Revenue fell to $38.6 million for the quarter (down 14.2% year-over-year) and $80.2 million for the six months (down 11.4%). The company recorded a net loss of $0.3 million for the quarter and $0.7 million for six months, equal to basic and diluted losses per share of $0.05 and $0.10, respectively. Cash and cash equivalents declined to $4.8 million at June 30, 2025. Operating expenses declined year-over-year (11.6% for the quarter; 9.6% for six months) as the company reduced labor and other costs and continued its transformation program, Project Elevate, which targets $16.0 million of cumulative savings. The company extended its asset-based revolving Credit Facility to June 30, 2028 and had $24.0 million of borrowing availability after letters of credit.